JP7530360B2 - Ｔｙｋ２阻害剤およびその使用 - Google Patents

Ｔｙｋ２阻害剤およびその使用 Download PDF

Info

Publication number
JP7530360B2
JP7530360B2 JP2021530887A JP2021530887A JP7530360B2 JP 7530360 B2 JP7530360 B2 JP 7530360B2 JP 2021530887 A JP2021530887 A JP 2021530887A JP 2021530887 A JP2021530887 A JP 2021530887A JP 7530360 B2 JP7530360 B2 JP 7530360B2
Authority
JP
Japan
Prior art keywords
nitrogen
compound
sulfur
oxygen
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530887A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020112937A5 (https=
JP2022509260A5 (https=
JP2022509260A (ja
Inventor
ジェレミー ロバート グリーンウッド，
クレッグ イー． マッセ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022509260A publication Critical patent/JP2022509260A/ja
Publication of JPWO2020112937A5 publication Critical patent/JPWO2020112937A5/ja
Publication of JP2022509260A5 publication Critical patent/JP2022509260A5/ja
Priority to JP2024120957A priority Critical patent/JP2024160253A/ja
Application granted granted Critical
Publication of JP7530360B2 publication Critical patent/JP7530360B2/ja
Priority to JP2025283785A priority patent/JP2026053668A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021530887A 2018-11-30 2019-11-27 Ｔｙｋ２阻害剤およびその使用 Active JP7530360B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024120957A JP2024160253A (ja) 2018-11-30 2024-07-26 Ｔｙｋ２阻害剤およびその使用
JP2025283785A JP2026053668A (ja) 2018-11-30 2025-12-26 Ｔｙｋ２阻害剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773620P 2018-11-30 2018-11-30
US62/773,620 2018-11-30
PCT/US2019/063510 WO2020112937A1 (en) 2018-11-30 2019-11-27 Tyk2 inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024120957A Division JP2024160253A (ja) 2018-11-30 2024-07-26 Ｔｙｋ２阻害剤およびその使用

Publications (4)

Publication Number Publication Date
JP2022509260A JP2022509260A (ja) 2022-01-20
JPWO2020112937A5 JPWO2020112937A5 (https=) 2022-12-05
JP2022509260A5 JP2022509260A5 (https=) 2022-12-05
JP7530360B2 true JP7530360B2 (ja) 2024-08-07

Family

ID=70848642

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021530887A Active JP7530360B2 (ja) 2018-11-30 2019-11-27 Ｔｙｋ２阻害剤およびその使用
JP2024120957A Pending JP2024160253A (ja) 2018-11-30 2024-07-26 Ｔｙｋ２阻害剤およびその使用
JP2025283785A Pending JP2026053668A (ja) 2018-11-30 2025-12-26 Ｔｙｋ２阻害剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024120957A Pending JP2024160253A (ja) 2018-11-30 2024-07-26 Ｔｙｋ２阻害剤およびその使用
JP2025283785A Pending JP2026053668A (ja) 2018-11-30 2025-12-26 Ｔｙｋ２阻害剤およびその使用

Country Status (8)

Country Link
US (2) US11053241B2 (https=)
EP (1) EP3886843A4 (https=)
JP (3) JP7530360B2 (https=)
CN (1) CN113271938A (https=)
AU (1) AU2019389025B2 (https=)
CA (1) CA3120866A1 (https=)
IL (1) IL283409B1 (https=)
WO (1) WO2020112937A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
JP7530360B2 (ja) 2018-11-30 2024-08-07 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF
EP4308556A4 (en) 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
TW202425965A (zh) * 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
CN115974751A (zh) * 2022-12-13 2023-04-18 山东能源集团新材料有限公司 一种吡拉西坦制备方法及系统
AU2023410062A1 (en) * 2022-12-22 2025-08-07 Protekt Therapeutics Ltd. Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors
WO2025010294A2 (en) * 2023-07-03 2025-01-09 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as tyk2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11878978B1 (en) 2023-09-06 2024-01-23 King Faisal University Pyrrolo[2,3-c]quinoline compounds as CK2 inhibitors
CN117342955A (zh) * 2023-10-08 2024-01-05 盐城师范学院 一种制备4’-甲基-联苯-2-胺的方法
WO2025222103A1 (en) * 2024-04-19 2025-10-23 Raythera, Inc. Stat6 modulators and methods of uses thereof
WO2025264818A1 (en) * 2024-06-20 2025-12-26 Raythera, Inc. Stat6 modulators and methods of uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512729A (ja) 1997-08-05 2001-08-28 ファイザー・プロダクツ・インク 神経ペプチドＹ受容体アンタゴニストとしての４−アミノピロ−ル（３，２−ｄ）ピリミジン
WO2006011670A1 (ja) 2004-07-28 2006-02-02 Takeda Pharmaceutical Company Limited ピロロ［２，３－ｃ］ピリジン化合物、その製造方法および用途
JP2017514838A (ja) 2014-05-01 2017-06-08 ノバルティス アーゲー Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物
WO2018031434A1 (en) 2016-08-08 2018-02-15 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2018089695A1 (en) 2016-11-11 2018-05-17 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
CA2569887A1 (en) * 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
EP3080131B1 (en) 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3848370B1 (en) * 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
JP7530360B2 (ja) 2018-11-30 2024-08-07 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512729A (ja) 1997-08-05 2001-08-28 ファイザー・プロダクツ・インク 神経ペプチドＹ受容体アンタゴニストとしての４−アミノピロ−ル（３，２−ｄ）ピリミジン
WO2006011670A1 (ja) 2004-07-28 2006-02-02 Takeda Pharmaceutical Company Limited ピロロ［２，３－ｃ］ピリジン化合物、その製造方法および用途
JP2017514838A (ja) 2014-05-01 2017-06-08 ノバルティス アーゲー Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物
WO2018031434A1 (en) 2016-08-08 2018-02-15 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2018089695A1 (en) 2016-11-11 2018-05-17 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use

Also Published As

Publication number Publication date
EP3886843A4 (en) 2022-08-31
IL283409A (en) 2021-07-29
IL283409B1 (en) 2026-03-01
AU2019389025B2 (en) 2025-07-24
US11834449B2 (en) 2023-12-05
CN113271938A (zh) 2021-08-17
CA3120866A1 (en) 2020-06-04
JP2026053668A (ja) 2026-03-25
AU2019389025A1 (en) 2021-06-17
US11053241B2 (en) 2021-07-06
EP3886843A1 (en) 2021-10-06
US20220106306A1 (en) 2022-04-07
JP2022509260A (ja) 2022-01-20
WO2020112937A1 (en) 2020-06-04
US20200172540A1 (en) 2020-06-04
JP2024160253A (ja) 2024-11-13

Similar Documents

Publication Publication Date Title
JP7530360B2 (ja) Ｔｙｋ２阻害剤およびその使用
JP7498200B2 (ja) Ｔｙｋ２阻害剤およびその使用
JP7699052B2 (ja) Ｔｙｋ２阻害剤およびその使用
US20230391797A1 (en) Tyk2 inhibitors and uses thereof
EP4076524A2 (en) Irak degraders and uses thereof
AU2019360941A1 (en) TYK2 inhibitors and uses thereof
CN115448916B (zh) Tyk2抑制剂及其用途
HK40055822B (en) Tyk2 inhibitors and uses thereof
HK40055822A (en) Tyk2 inhibitors and uses thereof
HK40009936B (en) Tyk2 inhibitors and uses thereof
HK40009936A (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240222

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240726

R150 Certificate of patent or registration of utility model

Ref document number: 7530360

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150